Ennio Antonio Chiocca

List of Publications by Year
in descending order

180	10,441	53794	36028
papers	citations	45 h-index	97 g-index

184	184	184	13894
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro-Oncology, 2022, 24, 101-113.	1.2	38
2	Neurosurgery Research and Education Foundation funding conversion to National Institutes of Health funding. Journal of Neurosurgery, 2022, 136, 287-294.	1.6	2
3	The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 63-75.	2.2	1
4	Virotherapy treatment of central nervous system tumors. , 2022, , 55-71.		0
5	Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. Neuro-Oncology, 2022, 24, 951-963.	1.2	44
6	Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles. ACS Nano, 2022, 16, 1940-1953.	14.6	58
7	Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. , 2022, 10, e003368.		9
8	Advances in local therapy for glioblastoma â€" taking the fight to the tumour. Nature Reviews Neurology, 2022, 18, 221-236.	10.1	106
9	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro-Oncology, 2022, 24, 1140-1149.	1.2	13
10	Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy. IScience, 2022, 25, 104395.	4.1	23
11	Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nature Communications, 2022, 13, 2810.	12.8	10
12	Abstract 6388: The effect of oncolytic virus therapy on neoantigen specific immune responses. Cancer Research, 2022, 82, 6388-6388.	0.9	0
13	Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.. Journal of Clinical Oncology, 2022, 40, 2012-2012.	1.6	2
14	STING activation promotes robust immune response and NK cellâ€"mediated tumor regression in glioblastoma models. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	44
15	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clinical Cancer Research, 2021, 27, 276-287.	7.0	100
16	Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican. Advanced Therapeutics, 2021, 4, 2000244.	3.2	11
17	Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. Neuro-Oncology Advances, 2021, 3, vdab027.	0.7	13
18	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. Neuro-Oncology, 2021, 23, 506-507.	1.2	0

#	Article	IF	Citations
19	Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology, 2021, 41, 381-468.	2.4	8
20	Introduction. Gene and viral therapy for glioblastoma multiforme. Neurosurgical Focus, 2021, 50, E1.	2.3	0
21	Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells. Cancers, 2021, 13, 1287.	3.7	8
22	Biographies of international women leaders in neurosurgery. Neurosurgical Focus, 2021, 50, E19.	2.3	5
23	Inhibitory CD161 receptor identified in glioma-infiltrating TÂcells by single-cell analysis. Cell, 2021, 184, 1281-1298.e26.	28.9	210
24	Targeting glioma-initiating cells via the tyrosine metabolic pathway. Journal of Neurosurgery, 2021, 134, 721-732.	1.6	23
25	The 1994 National Cancer Instituteâ€™s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.. Journal of Clinical Oncology, 2021, 39, 2003-2003.	1.6	0
26	Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.. Journal of Clinical Oncology, 2021, 39, 2014-2014.	1.6	10
27	First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.. Journal of Clinical Oncology, 2021, 39, 2009-2009.	1.6	3
28	Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database. Neurosurgery, 2021, 89, 196-203.	1.1	2
29	Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.. Journal of Clinical Oncology, 2021, 39, 2006-2006.	1.6	5
30	The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies. Viruses, 2021, 13, 1158.	3.3	16
31	Cytomegalovirus infection of glioblastoma cells leads to NF-Î°B dependent upregulation of the c-MET oncogenic tyrosine kinase. Cancer Letters, 2021, 513, 26-35.	7.2	2
32	Glial and myeloid heterogeneity in the brain tumour microenvironment. Nature Reviews Cancer, 2021, 21, 786-802.	28.4	83
33	CLRM-05. DRUG-RELEASING MICRODEVICES TO PREDICT RESPONSES TO TARGETED THERAPIES IN PATIENTS WITH GLIOMAS. Neuro-Oncology Advances, 2021, 3, iv2-iv2.	0.7	0
34	Unique challenges for glioblastoma immunotherapyâ€”discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
35	An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. Nature Communications, 2021, 12, 5908.	12.8	56
36	EXTH-61. MODULATION OF THE IL-27 RECEPTOR SIGNALING PATHWAY IN GLIOBLASTOMA AND ONCOLYTIC VIROTHERAPY. Neuro-Oncology, 2021, 23, vi177-vi177.	1.2	0

#	Article	IF	Citations
37	EXTH-81. STING ACTIVATION PROMOTES ROBUST IMMUNE RESPONSE AND TUMOR REGRESSION IN GLIOBLASTOMA MODELS. Neuro-Oncology, 2021, 23, vi182-vi182.	1.2	0
38	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-Oncology, 2021, 23, vi59-vi59.	1.2	4
39	CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi54-vi54.	1.2	4
40	CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE. Neuro-Oncology, 2021, 23, vi68-vi69.	1.2	0
41	CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi53-vi54.	1.2	1
42	CSIG-19. DISRUPTION OF DNA DAMAGE RESPONSE MODULATES THE EFFICACY OF LOCAL IMMUNOTHERAPIES IN EXPERIMENTAL GLIOMA. Neuro-Oncology, 2021, 23, vi37-vi37.	1.2	0
43	IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS. Neuro-Oncology, 2021, 23, vi97-vi97.	1.2	4
44	CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG). Neuro-Oncology, 2021, 23, vi52-vi52.	1.2	1
45	TAMI-35. DETECTING SINGLE-CELL INTERACTIONS IN ORGANOTYPIC CULTURES OF GLIOBLASTOMA USING BARCODED RABIES VIRUS. Neuro-Oncology, 2021, 23, vi205-vi205.	1.2	0
46	DDRE-18. THERAPEUTIC EFFECTS OF TASQUINIMOD ON GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi78-vi78.	1.2	0
47	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii9-ii9.	0.7	0
48	Redesigned reporter gene for improved proton exchange-based molecular MRI contrast. Scientific Reports, 2020, 10, 20664.	3.3	12
49	HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials. Cancers, 2020, 12, 3514.	3.7	38
50	Hypoxic Roadmap of Glioblastomaâ€"Learning about Directions and Distances in the Brain Tumor Environment. Cancers, 2020, 12, 1213.	3.7	10
51	Cytomegalovirus Encephalopathy during Brain Tumor Irradiation. Clinical Cancer Research, 2020, 26, 3077-3078.	7.0	1
52	Immune Escape Mediated by Exosomal PDâ€Ł1 in Cancer. Advanced Biology, 2020, 4, e2000017.	3.0	19
53	A Platinum(IV) Prodrugâ€"Perfluoroaryl Macrocyclic Peptide Conjugate Enhances Platinum Uptake in the Brain. Journal of Medicinal Chemistry, 2020, 63, 6741-6747.	6.4	20
54	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Molecular Cell, 2020, 78, 1207-1223.e8.	9.7	43

#	Article	IF	Citations
55	Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NFâ€ºB/STAT3 Signaling. Advanced Biology, 2020, 4, 1900312.	3.0	15
56	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. International Journal of Molecular Sciences, 2020, 21, 1931.	4.1	20
57	Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Scientific Reports, 2020, 10, 5095.	3.3	28
58	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
59	KLF4K409Qâ€“mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment. Acta Neuropathologica Communications, 2020, 8, 41.	5.2	25
60	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	27.8	374
61	Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas.. Journal of Clinical Oncology, 2020, 38, 3040-3040.	1.6	1
62	National Institute of Neurological Disorders and Stroke: current funding status, opportunities, challenges, emerging scientific advances, and recommendations for neurosurgery. Journal of Neurosurgery, 2020, 133, 1264-1269.	1.6	7
63	Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.. Journal of Clinical Oncology, 2020, 38, 2510-2510.	1.6	3
64	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Science Translational Medicine, 2019, 11, .	12.4	170
65	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 2019, 85, E607-E608.	1.1	20
66	Frameless Stereotactic Navigation during Insular Glioma Resection using Fusion of Three-Dimensional Rotational Angiography and Magnetic Resonance Imaging. World Neurosurgery, 2019, 126, 322-330.	1.3	11
67	Proteomic Analysis Implicates Vimentin in Glioblastoma Cell Migration. Cancers, 2019, 11, 466.	3.7	24
68	Molecular responses to immune checkpoint blockade in glioblastoma. Nature Medicine, 2019, 25, 359-361.	30.7	35
69	Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. ACS Nano, 2019, 13, 4028-4040.	14.6	147
70	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. Journal of Extracellular Vesicles, 2019, 8, 1588555.	12.2	86
71	Pneumatosis Intestinalis After Molecular-Targeted Therapy. World Neurosurgery, 2019, 125, 312-315.	1.3	9
72	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565, 234-239.	27.8	956

#	Article	IF	Citations
73	Characterization of single microvesicles in plasma from glioblastoma patients. Neuro-Oncology, 2019, 21, 606-615.	1.2	72
74	An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature Biotechnology, 2019, 37, 45-54.	17.5	56
75	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. Neuro-Oncology, 2019, 21, 14-25.	1.2	69
76	The multiple protective roles and molecular mechanisms of melatonin and its precursor N-acetylserotonin in targeting brain injury and liver damage and in maintaining bone health. Free Radical Biology and Medicine, 2019, 130, 215-233.	2.9	59
77	Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clinical Cancer Research, 2019, 25, 290-299.	7.0	88
78	Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis. Journal of Clinical Investigation, 2019, 129, 1671-1683.	8.2	52
79	Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.. Journal of Clinical Oncology, 2019, 37, 2020-2020.	1.6	4
80	Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.. Journal of Clinical Oncology, 2019, 37, 2053-2053.	1.6	0
81	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Science Advances, 2018, 4, eaar2766.	10.3	416
82	Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clinical Cancer Research, 2018, 24, 2574-2584.	7.0	40
83	Adult Tethered Cord Syndrome Following Chiari Decompression. World Neurosurgery, 2018, 112, 205-208.	1.3	6
84	Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano, 2018, 12, 494-503.	14.6	256
85	Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and inÂvivo mouse models. Cancer Letters, 2018, 416, 138-148.	7.2	29
86	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Scientific Reports, 2018, 8, 208.	3.3	24
87	Endoscopic Endonasal Resection of a Suprasellar Pituitary Adenoma Mimicking Tuberculum Sellae Meningioma in a Patient with an Intrasellar Persistent Trigeminal Artery. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S285-S286.	0.8	0
88	Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.. OncoImmunology, 2018, 7, e1407897.	4.6	22
89	DDIS-26. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2018, 20, vi74-vi74.	1.2	1
90	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi140-vi141.	1.2	0

#	Article	IF	Citations
91	TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2018, 20, vi271-vi271.	1.2	0
92	ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL. Neuro-Oncology, 2018, 20, vi3-vi4.	1.2	2
93	IMMU-02. ONCOLYTIC HSV THERAPY ENHANCES GLIOBLASTOMA CONTROL VIA THE EXPANSION OF FUNCTIONAL TUMOR-SPECIFIC T CELLS AND MODULATION OF MYELOID CELL POPULATION. Neuro-Oncology, 2018, 20, vi121-vi121.	1.2	0
94	EXTH-53. IN VIVO QUANTITATIVE ANALYSIS OF ONCOLYTIC VIRUS-TUMOR KINETICS. Neuro-Oncology, 2018, 20, vi96-vi96.	1.2	0
95	ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS. Neuro-Oncology, 2018, 20, vi8-vi8.	1.2	0
96	Immunotherapy for glioblastoma: going viral. Nature Medicine, 2018, 24, 1094-1096.	30.7	25
97	Viruses in cancer therapy â€" from benchwarmers to quarterbacks. Nature Reviews Clinical Oncology, 2018, 15, 657-658.	27.6	17
98	Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.. Journal of Clinical Oncology, 2018, 36, 3038-3038.	1.6	1
99	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2003-2003.	1.6	1
100	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro-Oncology, 2017, 19, now253.	1.2	35
101	MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. Stem Cell Reports, 2017, 8, 1497-1505.	4.8	58
102	MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. Cell Reports, 2017, 19, 2026-2032.	6.4	33
103	Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. Nature Communications, 2017, 8, 15623.	12.8	224
104	Perfluoroareneâ€"Based Peptide Macrocycles to Enhance Penetration Across the Bloodâ€"Brain Barrier. Journal of the American Chemical Society, 2017, 139, 15628-15631.	13.7	60
105	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. Journal of Neuro-Oncology, 2017, 135, 581-591.	2.9	15
106	Oncolytic Viruses in Cancer Treatment. JAMA Oncology, 2017, 3, 841.	7.1	426
107	IMMU-12. THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID AUGMENTS THE SUSCEPTIBILITY OF ONCOLYTIC VIRUS-INFECTED GLIOBLASTOMA CELLS TO PD-1 BLOCKADE THERAPY. Neuro-Oncology, 2017, 19, vi115-vi115.	1.2	0
108	IMMU-10. EXPRESSION OF PD-L2, IN GLIOBLASTOMA; IMPLICATIONS AS AÂBIOMARKER FOR IMMUNOTHERAPY. Neuro-Oncology, 2017, 19, vi114-vi114.	1.2	0

#	Article	IF	Citations
109	Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2044-2044.	1.6	8
110	Immunotherapy for glioblastoma: on the sidelines or in the game?. Discovery Medicine, 2017, 24, 201-208.	0.5	31
111	A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget, 2016, 7, 27764-27777.	1.8	188
112	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e132-e139.	3.8	13
113	CBIO-12. SIX EXTRACELLULAR VESICLE RELATED GENES CAN EXPLAIN THE PRO-TUMORIGENIC BEHAVIOR OF HETEROGENEOUS HIGH GRADE GLIOMAS. Neuro-Oncology, 2016, 18, vi37-vi37.	1.2	0
114	BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. Scientific Reports, 2016, 6, 20189.	3.3	38
115	Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. Cancer Research, 2016, 76, 2876-2881.	0.9	85
116	Design of a Microfluidic Chip for Magnetic-Activated Sorting of One-Bead-One-Compound Libraries. ACS Combinatorial Science, 2016, 18, 271-278.	3.8	8
117	Glioma and microglia, a double entendre. Nature Immunology, 2016, 17, 1240-1242.	14.5	20
118	IMST-05. NOVEL CAR-T CELLS TARGETING THE EXTRACELLULAR MATRIX OF GLIOBLASTOMA INDUCE STRONG ANTI-TUMOR IMMUNE RESPONSE. Neuro-Oncology, 2016, 18, vi86-vi87.	1.2	0
119	The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. Cell Reports, 2016, 15, 2500-2509.	6.4	156
120	Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors. Cellular and Molecular Neurobiology, 2016, 36, 361-376.	3.3	36
121	Experimental therapies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 183-197.	1.8	22
122	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro-Oncology, 2016, 18, 1137-1145.	1.2	126
123	A vaccine from plant virus proteins. Nature Nanotechnology, 2016, 11, 214-215.	31.5	21
124	Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.. Journal of Clinical Oncology, 2016, 34, 2052-2052.	1.6	2
125	ATPS-08DISCOVERY OF NOVEL GLIOMA-TARGETING PEPTIDES USING A HIGH-THROUGHPUT MICROFLUIDIC MAGNETIC-ACTIVATED SORTER. Neuro-Oncology, 2015, 17, v19.4-v19.	1.2	0
126	Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. Oncolytic Virotherapy, 2015, 4, 183.	6.0	16

#	Article	IF	Citations
127	A cross-talk network that facilitates tumor virotherapy. Nature Medicine, 2015, 21, 426-427.	30.7	1
128	Glucose-Based Regulation of miR-451/AMPK Signaling Depends on the OCT1 Transcription Factor. Cell Reports, 2015, 11, 902-909.	6.4	50
129	Skull Base Chordomas and Chondrosarcomas: A Population-Based Analysis. World Neurosurgery, 2015, 83, 468-470.	1.3	4
130	Extracranial growth of glioblastoma multiforme. Journal of Clinical Neuroscience, 2015, 22, 1521-1523.	1.5	25
131	Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. Current Opinion in Virology, 2015, 13, 25-32.	5.4	19
132	ATPS-98MONITORING ONCOLYTIC HSV-1 WITH NON-INVASIVE BIOLUMINESCENCE. Neuro-Oncology, 2015, 17, v40.1-v40.	1.2	0
133	IMPS-21EFFECT OF rQNestin 34.5 ONCOLYTIC HERPES VIRUS ON IMMUNE CHECKPOINT GENE EXPRESSION IN GLIOBLASTOMA CELLS AND EVALUATION OF THERAPEUTIC EFFICACY. Neuro-Oncology, 2015, 17, v117.4-v118.	1.2	0
134	Awake Craniotomy and Intraoperative MRI for Maximal Safe Resection in a Case of an Extensive Left Frontal and Insular Low-grade Glioma: 3-Dimensional Operative Video. Operative Neurosurgery, 2015, 11, 578-578.	0.8	2
135	Interferon-stimulated Gene 15 (ISG15) and ISG15-linked Proteins Can Associate with Members of the Selective Autophagic Process, Histone Deacetylase 6 (HDAC6) and SQSTM1/p62. Journal of Biological Chemistry, 2015, 290, 1485-1495.	3.4	85
136	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 384-389.	0.8	46
137	Modeling Cytomegalovirus Infection in Mouse Tumor Models. Frontiers in Oncology, 2015, 5, 61.	2.8	2
138	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports, 2015, 5, 11483.	3.3	270
139	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	1.2	40
140	Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. Journal of Clinical Oncology, 2015, 33, 2812-2814.	1.6	36
141	Awake right hemisphere brain surgery. Journal of Clinical Neuroscience, 2015, 22, 1921-1927.	1.5	6
142	TGFÎ² Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Research, 2015, 75, 5273-5282.	0.9	75
143	No Free Lunch: Secondary Neoplasms After Stereotactic Radiation. World Neurosurgery, 2015, 83, 330-331.	1.3	1
144	Academic Productivity in Today's Training Climate: A Fellowship's Impact. World Neurosurgery, 2015, 83, 328-329.	1.3	1

#	Article	IF	Citations
145	Belonging to a networkâ€”microRNAs, extracellular vesicles, and the glioblastoma microenvironment. Neuro-Oncology, 2015, 17, 652-662.	1.2	78
146	MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. Oncotarget, 2015, 6, 3770-3783.	1.8	42
147	Response to energy depletion: miR-451/AMPK loop. Oncotarget, 2015, 6, 17851-17852.	1.8	7
148	Modulation of Natural Killer Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor. Blood, 2015, 126, 210-210.	1.4	1
149	One size should not fit all: advancing toward personalized glioblastoma therapy. Discovery Medicine, 2015, 19, 471-7.	0.5	13
150	Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults. Molecular Therapy, 2014, 22, 1056-1062.	8.2	119
151	Targeting Glioblastoma Invasion with GSK-3 inhibitors: Rapid Effects on the EMT Marker Vimentin. Canadian Journal of Neurological Sciences, 2014, 41, S1-S2.	0.5	0
152	Predicting Outcomes: Recursive Partitioning Analysis (RPA) Prognostic Algorithm for Patients with Metastatic Sarcoma to the Brain. World Neurosurgery, 2014, 82, 1030-1032.	1.3	0
153	How Much Is Enough? The Question of Extent of Resection in Glioblastoma Multiforme. World Neurosurgery, 2014, 82, e109-e110.	1.3	15
154	Low-Grade Gliomas and Quality of Life. World Neurosurgery, 2014, 82, e133-e134.	1.3	2
155	Developmental expression of GPR3 in rodent cerebellar granule neurons is associated with cell survival and protects neurons from various apoptotic stimuli. Neurobiology of Disease, 2014, 68, 215-227.	4.4	31
156	From Localization to Pathways: The Continuing Evolution of Diffusion Tensor Imaging. World Neurosurgery, 2014, 82, e47-e48.	1.3	6
157	Immunotherapy advances for glioblastoma. Neuro-Oncology, 2014, 16, 1441-1458.	1.2	164
158	Oncolytic Viruses and Their Application to Cancer Immunotherapy. Cancer Immunology Research, 2014, 2, 295-300.	3.4	308
159	Who Benefits from Surgery for Brain Metastases?. World Neurosurgery, 2014, 82, e115-e116.	1.3	0
160	Neoplasm Development After Stereotactic Radiosurgery for Arteriovenous Malformations. World Neurosurgery, 2014, 82, 304-306.	1.3	2
161	Image-Guided Maximal Resection of Intrinsic Tumors. World Neurosurgery, 2014, 82, 604-605.	1.3	1
162	Extracellular Vesicles Modulate the Glioblastoma Microenvironment via a Tumor Suppression Signaling Network Directed by miR-1. Cancer Research, 2014, 74, 738-750.	0.9	197

#	Article	IF	Citations
163	Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2014, 32, 2065-2065.	1.6	1
164	Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma.. Journal of Clinical Oncology, 2014, 32, 3078-3078.	1.6	0
165	NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine, 2012, 18, 1827-1834.	30.7	164
166	Tannous et al. Respond:. Molecular Therapy, 2009, 17, 1311-1312.	8.2	1
167	A Phase I Trial of Ad.hIFN-Î² Gene Therapy for Glioma. Molecular Therapy, 2008, 16, 618-626.	8.2	114
168	The host response to cancer virotherapy. Current Opinion in Molecular Therapeutics, 2008, 10, 38-45.	2.8	46
169	Neurosurgical robotics: a review of brain and spine applications. Journal of Robotic Surgery, 2007, 1, 39-43.	1.8	38
170	A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. Molecular Therapy, 2004, 10, 958-966.	8.2	401
171	Neurosurgical Delivery of Chemotherapeutics, Targeted Toxins, Genetic and Viral Therapies in Neuro-Oncology. Journal of Neuro-Oncology, 2004, 69, 101-117.	2.9	50
172	Guided genes for tumor warfare. Nature Biotechnology, 2002, 20, 235-236.	17.5	4
173	In vivo magnetic resonance imaging of transgene expression. Nature Medicine, 2000, 6, 351-354.	30.7	811
174	Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Therapy, 2000, 7, 1051-1059.	4.6	48
175	Multicolumn Infusion of Gene Therapy Cells into Human Brain Tumors: Technical Report. Neurosurgery, 2000, 46, 663-669.	1.1	19
176	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Medicine, 1999, 5, 881-887.	30.7	309
177	An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnology, 1998, 16, 444-448.	17.5	167
178	Gene Therapy for Brain Tumors. Brain Pathology, 1995, 5, 345-381.	4.1	93
179	Deep Sylvian Fissure Meningioma without Dural Attachment in an Adult. Neurosurgery, 1994, 35, 944-946.	1.1	28
180	The Current State of Glioma Data Registries. Neuro-Oncology Advances, 0, , .	0.7	1